Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The University of Western Australia is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners and are located in 3 distinct art units. FRONDA, CHRISTIAN L is identified as the busiest examiner with 1 pending office action.
The distribution of 3 pending office actions across 3 distinct examiners and 3 distinct art units indicates a decentralized prosecution landscape. Each case is being handled by a different examiner in a different technical division of the USPTO. This requires the applicant to manage separate sets of examiner expectations and different sets of art unit-specific procedures.
FRONDA, CHRISTIAN L's role as the busiest examiner involves 1 pending office action, which is equal to the workload of the other examiners. This structure means that the company must be prepared for varied feedback and different examination timelines across its portfolio. The presence of 3 distinct art units suggests that the university's research spans multiple specialized areas within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRONDA, CHRISTIAN L | 1 | 82.4% | +14.2% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| WU, JULIE ZHEN QIN | 1 | 62.0% | +50.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18802964 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | FRONDA, CHRISTIAN L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | WU, JULIE ZHEN QIN | 12d |
| 18249934 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | FISCHER, JOSEPH | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | WU, JULIE ZHEN QIN | 12d |
| 18249934 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | FISCHER, JOSEPH | 26d |
| 18802964 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | FRONDA, CHRISTIAN L | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1658 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18802964 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | FRONDA, CHRISTIAN L | 1652 | §103DP | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18249934 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | FISCHER, JOSEPH | 1658 | §102§103§112 | Non-Final OA | 26d | Pending | Apr 20, 2023 |
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | WU, JULIE ZHEN QIN | 1643 | §102§103§112 | Final Rejection | 12d | Pending | Jun 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial